Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.58 | N/A | -32.72% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.58 | N/A | -32.72% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was defensive, highlighting the difficulties faced in the quarter. They did not provide detailed insights or future guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company acknowledged challenges in meeting earnings expectations.
PTC Therapeutics reported a larger-than-expected loss in earnings, leading to a 6.59% drop in stock price. The lack of revenue figures and guidance contributed to investor uncertainty. This performance may raise concerns about the company's financial health and future prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 5, 2014